Stock Track | Hims & Hers Health Soars 6.08% in Extended Trading on Potential FDA Leadership Change and Weight-Loss Drug Partnerships

Stock Track

May 11

Hims & Hers Health Inc. (HIMS) experienced a significant price increase of 6.08% in extended trading, reflecting strong investor sentiment.

The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.

Furthermore, the company's strategic partnerships in the weight-loss drug sector are fueling optimism. Hims & Hers Health has recently re-signed its agreement with Novo Nordisk and entered a new partnership with Eli Lilly, enhancing its capacity to distribute GLP-1 medications directly to consumers. This expansion aligns with strong market demand for weight-loss drugs, as evidenced by Novo Nordisk's robust quarterly sales performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1133274538"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133274538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133274538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 08:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133274538","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 6.08% in Extended Trading on Potential FDA Leadership Change and Weight-Loss Drug Partnerships","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant price increase of 6.08% in extended trading, reflecting strong investor sentiment.</p><p>The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.</p><p>Furthermore, the company's strategic partnerships in the weight-loss drug sector are fueling optimism. Hims & Hers Health has recently re-signed its agreement with Novo Nordisk and entered a new partnership with Eli Lilly, enhancing its capacity to distribute GLP-1 medications directly to consumers. This expansion aligns with strong market demand for weight-loss drugs, as evidenced by Novo Nordisk's robust quarterly sales performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 6.08% in Extended Trading on Potential FDA Leadership Change and Weight-Loss Drug Partnerships</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 6.08% in Extended Trading on Potential FDA Leadership Change and Weight-Loss Drug Partnerships\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 08:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant price increase of 6.08% in extended trading, reflecting strong investor sentiment.</p><p>The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.</p><p>Furthermore, the company's strategic partnerships in the weight-loss drug sector are fueling optimism. Hims & Hers Health has recently re-signed its agreement with Novo Nordisk and entered a new partnership with Eli Lilly, enhancing its capacity to distribute GLP-1 medications directly to consumers. This expansion aligns with strong market demand for weight-loss drugs, as evidenced by Novo Nordisk's robust quarterly sales performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1133274538","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133274538","pubTimestamp":1778458048,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant price increase of 6.08% in extended trading, reflecting strong investor sentiment.The surge is primarily driven by reports of a potential...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health因潜在FDA领导层变动和减肥药合作而在盘后交易中飙升6.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant price increase of 6.08% in extended trading, reflecting strong investor sentiment.The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.Furthermore, the company's strategic partnerships in the weight-loss drug sector are fueling optimism. Hims & Hers Health has recently re-signed its agreement with Novo Nordisk and entered a new partnership with Eli Lilly, enhancing its capacity to distribute GLP-1 medications directly to consumers. This expansion aligns with strong market demand for weight-loss drugs, as evidenced by Novo Nordisk's robust quarterly sales performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}